Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858846 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL9064347 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL27521995 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL27558317 | 0.87 | FFAR4 (0.50) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL9444912 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL31399530 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL31399643 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL8862852 | 0.87 | FFAR1 (0.55) | FFAR4FFAR1GPR84NFKB1FAAH | |
| SCHEMBL10927446 | 0.86 | GPR84 (0.40) | FFAR4ACACBACACAFFAR1GPR84 | |
| SCHEMBL28044557 | 0.86 | GPR84 (0.40) | FFAR4ACACBACACAFFAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | FFAR4 429/4885ACACB 143/4885ACACA 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.